Shares Magazine
11.86p-0.40 (-3.22%)15 Dec 2025, 12:48
Jump to:
Ixico PLC Fundamentals
| Company Name | Ixico PLC | Last Updated | 2025-12-15 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 92.669 m | Market Cap | £10.99 m |
| PE Ratio | 76.34 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0129 | Debt Equity Ratio | 0.0026 |
| Asset Equity Ratio | 1.1791 | Cash Equity Ratio | 0.3014 |
| Quick Ratio | 2.6412 | Current Ratio | 3.03 |
| Price To Book Value | 0.9672 | ROCE | 0 |
Ixico PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Ixico PLC Company Financials
| Assets | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tangible Assets | £167,000.00 | £313,000.00 | £518,000.00 | £817,000.00 |
| Intangible Assets | £7.18 m | £6.37 m | £6.15 m | £4.59 m |
| Investments | 0 | 0 | 0 | 0 |
| Total Fixed Assets | £7.61 m | £6.70 m | £6.70 m | £5.40 m |
| Stocks | 0 | 0 | 0 | 0 |
| Debtors | £1.90 m | £2.21 m | £1.67 m | £3.00 m |
| Cash & Equivalents | £3.54 m | £1.79 m | £4.03 m | £5.77 m |
| Other Assets | 0 | 0 | 0 | 0 |
| Total Assets | £13.84 m | £11.19 m | £12.99 m | £14.65 m |
| Liabilities | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Creditors within 1 year | £2.06 m | £1.57 m | £1.28 m | £1.74 m |
| Creditors after 1 year | £45,000.00 | £150,000.00 | £277,000.00 | £427,000.00 |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | £2.10 m | £1.72 m | £1.56 m | £2.16 m |
| Net assets | £11.74 m | £9.46 m | £11.43 m | £12.49 m |
| Equity | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Called up share capital | £927,000.00 | £484,000.00 | £484,000.00 | £482,000.00 |
| Share Premium | £95.51 m | £92.26 m | £92.26 m | £92.26 m |
| Profit / Loss | -£2.45 m | -£2.09 m | -£1.36 m | £885,000.00 |
| Other Equity | £11.74 m | £9.46 m | £11.43 m | £12.49 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | £11.74 m | £9.46 m | £11.43 m | £12.49 m |
| Ratios | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Debt Ratio | £0.00 | £0.02 | £0.02 | £0.03 |
| Debt-to-Equity | £0.00 | £0.02 | £0.02 | £0.03 |
| Assets / Equity | 1.1791 | 1.1791 | 1.1791 | 1.1791 |
| Cash / Equity | 0.3014 | 0.3014 | 0.3014 | 0.3014 |
| EPS | -£0.02 | -£0.04 | -£0.02 | £0.02 |
| Cash Flow | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash from operating activities | -£1.01 m | -£1.73 m | £302,000.00 | £1.42 m |
| Cashflow before financing | £2.50 m | -£1.87 m | £146,000.00 | £1.31 m |
| Increase in Cash | £1.75 m | -£2.24 m | -£1.72 m | -£929,000.00 |
| Income | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Turnover | £6.53 m | £5.77 m | £6.67 m | £8.64 m |
| Cost of sales | £3.35 m | £3.06 m | £3.40 m | £3.40 m |
| Gross Profit | £3.18 m | £2.71 m | £3.27 m | £5.24 m |
| Operating Profit | -£2.55 m | -£2.15 m | -£1.44 m | £908,000.00 |
| Pre-Tax profit | -£2.45 m | -£2.09 m | -£1.36 m | £885,000.00 |
Ixico PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medicalimaging operations and post-marketing surveillance. |
| Latest Interim Date | 20 May 2025 |
| Latest Fiscal Year End Date | 9 Dec 2025 |
Ixico PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2014-02-28 | Mr. Alistair Henderson Taylor | Non-Executive Director,Chairman |
| 2014-02-28 | Mr. Roger Hickling | Executive Director,Research and Development Director |
| 2012-05-30 | Mr. Alexander Dunbar Sandy Morrison | Non-Executive Director |
| 2016-09-16 | Dr. Andrew John McGlashan Richards CBE | Non-Executive Director,Chairman |
| 2014-02-28 | Dr. Peter Robin Blower | Non-Executive Director |
| 2019-12-13 | Mr. Timothy Sharpington | Non-Executive Director |
| 2007-06-07 | Dr. Paul Michael Whitney BSc,PhD,MBA | Non-Executive Director,Chairman |
| 2011-08-09 | Dr. Richard Peter Dixey, B.A.,M. Sc.,PhD | Executive Director,Chief Executive Officer |
| 2022-04-29 | Mr. John Bradshaw | Non-Executive Director |
| 2024-01-25 | Dr. Charles Alexander Evan Spicer | Non-Executive Director,Chairman |
| 2011-08-09 | Mr. Piers John Morgan | Executive Director,Chief Financial Officer |
| 2011-08-09 | Dr. Daryl David Rees, B.Sc. ,M.Sc.,PhD | Executive Director,Chief Executive Officer |
| 2018-01-22 | Professor Derek Lionel Glendon Hill | Executive Director |
| 2016-01-08 | Ms. Maina Bhaman | Non-Executive Director |
| 2021-12-17 | Ms. Susan Day Lowther | Executive Director,Chief Financial Officer and Company Secretary |
| 2025-12-09 | Mr. Mark Robert Warne | Non-Executive Director,Chairman |
| 2024-08-16 | Mr. Giulio Cerroni | Executive Director,Chief Executive Officer |
| 2025-12-09 | Mr. Grant Robert Nash | Executive Director,Chief Financial Officer, Chief Operating Officer and Company Secretary |
| 2025-12-09 | Dr. Dipti Mahendra Amin | Non-Executive Director |
| 2025-12-09 | Mr. Bram Goorden | Executive Director,Chief Executive Officer |
| 2025-12-09 | Ms. Katherine Jane Rogers | Non-Executive Director |
Ixico PLC Contact Details
| Company Name | IXICO PLC |
|---|---|
| Address | 15 Long Lane, 4th Floor, Griffin Court, London, EC1A 9PN |
| Telephone | +44 2037637499 |
| Website | https://www.ixico.com |
Ixico PLC Advisors
| Stockbroker | Shore Capital Stockbrokers Ltd |
|---|---|
| Phone | +44 2074084050 |
| Fax | +44 2074084091 |
| Nominated Adviser | Shore Capital & Corporate Ltd |
|---|---|
| Phone | +44 2074084050 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Auditor | Grant Thornton UK LLP |
|---|---|
| Phone | +44 1223225600 |
| Fax | +44 1223225619 |
| Solicitor | Bristows |
|---|---|
| Phone | +44 2074008000 |
| Fax | +44 2074008050 |
| Registrar | Equiniti Ltd. |
|---|---|
| Phone | +44 1214157082 |
| Remuneration Consultant | New Bridge Street |
|---|---|
| Phone | +44 2070869341 |
| Fax | +44 2070869341 |
| Financial Adviser | Rothschild |
|---|---|
| Phone | +44 2072805000 |
| Bank | HBOS PLC |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Frasers Group PLC | 676.50 | 7.47 |
| B&M European Value Retail S.A. | 163.80 | 4.43 |
| Foresight Solar Fund Limited | 64.90 | 4.01 |
| Antofagasta PLC | 3,037.70 | 3.61 |
| Burberry Group PLC | 1,312.50 | 3.14 |
| Ocado Group PLC | 232.59 | 3.14 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Oxford Biomedica PLC | 602.91 | -3.69 |
| Ceres Power Holdings PLC | 265.86 | -2.40 |
| North Atlantic Smaller Companies Investment Trust PLC | 359.00 | -1.64 |
| Oxford Nanopore Technologies PLC | 123.00 | -1.44 |
| Ncc Group PLC | 137.20 | -1.15 |
| Hikma Pharmaceuticals PLC | 1,500.00 | -1.06 |